Apr 29, 2020
Windtree Announces First Patient Enrolled in AEROSURF® Bridging Study for the Treatment of Respiratory Distress Syndrome
Mar 24, 2020
Windtree to Pursue Clinical Study of Lung Injury Treatment in COVID-19 Patients with its KL4 Surfactant Therapy
Jul 23, 2018
Windtree Announces Completion of New Design Development for its Aerosol Delivery System (ADS) including Successful Performance Testing
May 31, 2018
Windtree Therapeutics' Aerosolized KL4 Surfactant Preclinical Data in Influenza Presented at the 2018 American Thoracic Society Meeting
May 22, 2018
Windtree Receives $0.7 Million SBIR Grant in Continuing Support of the AEROSURF® Phase 2b Clinical Trial Completion
Dec 28, 2017
Windtree Therapeutics to Provide AEROSURF® and Business Updates
Dec 21, 2017
Windtree Therapeutics Announces Reverse Stock Split
Dec 12, 2017
Windtree Therapeutics to Participate in Corporate Access Event in San Francisco, January 8 - 10, 2018
Dec 07, 2017
Aerogen Pharma and Lyomark Pharma Partner to Develop Inhaled Surfactant, Begin a Phase 2 Clinical Trial
Nov 01, 2017
Windtree Successfully Completes Financial Restructuring Program
Jul 25, 2017
AzarGen Biotechnologies Granted European Patent for Plant-Made PRODUCTION OF RECOMBINANT HUMAN SURFACTANT PROTEIN-B
Jun 12, 2017
Windtree Therapeutics and Lee's Pharmaceutical (HK) Limited Enter Into Exclusive License and Collaboration Agreement for Development and Commercialization of KL4 Surfactant Technology Platform in Asia
Jun 01, 2017
Windtree Announces Successful Completion of Enrollment in AEROSURF® Phase 2b Clinical Trial for the Treatment of Respiratory Distress Syndrome (RDS) in Premature Infants